MIRM Q4 2025 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$149M+49.8% YoY

Gross Profit

$121M81.0% margin

Operating Income

-$5M-3.1% margin

Net Income

-$6M-3.8% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+12.0%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$5M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$843M

Total Liabilities

$528M

Stockholders' Equity

$315M

Cash & Equivalents

$297M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$149M	$99M	+49.8%
Gross Profit	$121M	$77M	+57.4%
Operating Income	-$5M	-$24M	+81.1%
Net Income	-$6M	-$24M	+75.9%

Revenue Segments

Product

$149M100%

Geographic Segments

UNITED STATES

$115M100%